Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and Entinostat in Resected Stage I NSCLC
NCT01207726Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Sep 2010
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Azacitidine + Entinostat with Standard of Care (2 arms). Primary endpoint: Disease-free Survival at 3 years. Started Sep 2010; status: terminated.
02
Drugs
azacitidineentinostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01207726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01207726.